keyword
MENU ▼
Read by QxMD icon Read
search

Wearable Defibrillator

keyword
https://www.readbyqxmd.com/read/29180909/wearable-cardioverter-defibrillators-for-the-prevention-of-sudden-cardiac-arrest-a-health-technology-assessment-and-patient-focus-group-study
#1
Sabine Ettinger, Michal Stanak, Piotr Szymański, Claudia Wild, Romana Tandara Haček, Darija Erčević, Renata Grenković, Mirjana Huić
Aim: To summarize the evidence on clinical effectiveness and safety of wearable cardioverter defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest in patients at risk. Methods: We performed a systematic literature search in databases including MEDLINE via OVID, Embase, the Cochrane Library, and CRD (DARE, NHS-EED, HTA). The evidence obtained was summarized according to GRADE methodology. A health technology assessment (HTA) was conducted using the HTA Core Model® for rapid relative effectiveness assessment...
2017: Medical Devices: Evidence and Research
https://www.readbyqxmd.com/read/29178898/the-wearable-cardioverter-defibrillator-as-a-bridge-to-reimplantation-in-patients-with-icd-or-crt-d-related-infections
#2
L Castro, S Pecha, M Linder, J Vogler, N Gosau, C Meyer, S Willems, H Reichenspurner, S Hakmi
BACKGROUND: The approach to treat device infection in patients with implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) is a challenging procedure. Optimal treatment is complete extraction of the infected device. To protect these patients from sudden cardiac arrest while waiting for reimplantation and to avoid recurrent infection, a wearable cardioverter defibrillator (WCD) seems to be a valuable solution. Therefore, we investigated the management and outcome of patients with ICD or CRT-D infections using the WCD as a bridge to re-implantation after lead extraction procedures...
November 25, 2017: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/29153771/outcome-of-patients-with-in-hospital-ventricular-tachycardia-and-ventricular-fibrillation-arrest-while-using-a-wearable-cardioverter-defibrillator
#3
Kenneth A Ellenbogen, Chingping Wan, David M Shavelle
In-hospital sudden cardiac arrests occurring during nighttime and weekend hours or within unmonitored hospital areas have been reported to have a poorer outcomes than monitored cardiac arrest. This study sought to assess the outcome of in-hospital ventricular tachycardia (VT) and ventricular fibrillation (VF) arrest by time of day, day of week, and within-hospital location when using a wearable cardioverter defibrillator (WCD). We retrospectively identified and reviewed consecutive in-hospital VT/VF arrests from January 2011 to May 2015 experienced by patients wearing a WCD using the manufacturer's postmarket registry...
November 16, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/29124430/oversensing-of-the-wearable-cardioverter-defibrillator-during-bipolar-ventricular-stimulation
#4
Martin Manninger, Tanja Odeneg, Friedrich Fruhwald, Helmut Brussee, Daniel Scherr
The wearable cardioverter defibrillator (WCD) is a temporary treatment option for patients with potentially reversible risk of sudden cardiac death. This case demonstrates a pitfall during WCD usage in a pacemaker-dependent patient as well as a possible solution allowing continuation of WCD therapy. Bipolar stimulation may lead to double counting of the WCD detection algorithm resulting in false alarm or inappropriate therapy.
November 9, 2017: Wiener Klinische Wochenschrift
https://www.readbyqxmd.com/read/29072998/real-world-utilization-and-impact-of-the-wearable-cardioverter-defibrillator-in-a-community-setting
#5
Aditi Naniwadekar, Talal Alnabelsi, Kamal Joshi, Edinrin Obasare, Allan Greenspan, Sumeet Mainigi
INTRODUCTION: The wearable cardioverter-defibrillator (WCD) is used in patients at risk for sudden cardiac death (SCD) but not immediate candidates for intracardiac defibrillator (ICD) implantation. METHODS: We performed a single center retrospective study of patients prescribed WCD upon hospital discharge from January 2002 to October 2015. Clinical characteristics were obtained from the hospital electronic database and device data from Zoll LifeVest database. RESULTS: Of 140 patients, 62% were men, 85...
May 2017: Indian Pacing and Electrophysiology Journal
https://www.readbyqxmd.com/read/29071387/-ventricular-arrhythmias-what-has-been-confirmed-in-therapy
#6
REVIEW
D Duncker, J Bauersachs, C Veltmann
Ventricular arrhythmias include a wide range of potentially benign single ventricular premature contractions to ventricular tachycardia and ventricular fibrillation with a risk for sudden cardiac death. The diagnosis of ventricular arrhythmia is made by 12-lead electrocardiogram, 24 h Holter monitoring, an external or implantable loop recorder, or during in-hospital monitoring. Especially the diagnosis of wide complex tachycardias is challenging in terms of differentiating between ventricular tachycardia and supraventricular tachycardia with aberrant atrioventricular conduction...
October 25, 2017: Der Internist
https://www.readbyqxmd.com/read/29064577/wearable-cardioverter-defibrillators-in-schools-a-guide-for-parents-and-educators
#7
Ashley E Burch, David S Spar, Samuel F Sears
Keeping children safe is a goal for everyone. To stay safe, some children need a wearable cardioverter defibrillator (WCD). WCDs protect individuals who are at risk for life-threatening arrhythmias. The LifeVest(®) (ZOLL, Pittsburgh, PA) is a WCD that identifies, records, and treats potentially life-threatening abnormal heartbeats, or arrhythmias. The WCD will provide electrical energy to the heart with up to five high energy shocks if a potentially dangerous cardiac arrhythmia is detected. This type of arrhythmia, if not treated within a short time period (less than 2 minutes), can result in disruption of blood flow to the brain and other vital organs (that is, a sudden cardiac arrest), and death can occur within minutes...
October 24, 2017: Pacing and Clinical Electrophysiology: PACE
https://www.readbyqxmd.com/read/28993851/usefulness-of-the-wcd-in-patients-with-suspected-tachymyopathy
#8
Julia W Erath, Mate Vamos, Alexander P Benz, Stefan H Hohnloser
AIMS: The wearable cardioverter defibrillator (WCD) is used for temporary protection of patients deemed to be at high risk for sudden death. There is limited experience regarding the clinical development of patients with tachymyopathy. We aimed to evaluate the clinical development of tachymyopathy patients protected with a WCD in a single-center non-randomized patient cohort. METHODS AND RESULTS: We fitted 130 consecutive patients deemed to be at high risk for ventricular tachyarrhythmias with the WCD...
October 9, 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/28984287/the%C3%A2-lifevest-wearable-defibrillator-for-noninvasive-prevention-of-sudden-arrhythmic-death-syndrome-the%C3%A2-first-polish-case-of-an-adequate-lifevest-intervention
#9
Michał Chudzik, Łukasz Szyda, Bożena Urbanek, Jerzy K Wranicz, Jarosław D Kasprzak
No abstract text is available yet for this article.
September 29, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28969980/ventricular-arrhythmia-occurrence-and-compliance-in-patients-treated-with-the-wearable-cardioverter-defibrillator-following-percutaneous-coronary-intervention
#10
Jérémie Barraud, Pauline Pinon, Marc Laine, Jennifer Cautela, Morgane Orabona, Linda Koutbi, Johan Pinto, Franck Thuny, Frederic Franceschi, Franck Paganelli, Laurent Bonello, Michaël Peyrol
BACKGROUND: The wearable cardioverter defibrillator (WCD) is a life-saving therapy in patients with high risk of arrhythmic death. We aimed to evaluate ventricular arrhythmia (VA) occurrence rate and compliance with the WCD during the first 90 days following myocardial revascularisation with percutaneous coronary intervention (PCI) in patients with left ventricular ejection fraction (LVEF) <30%. METHODS: From September 2015 to November 2016, clinical characteristics, WCD recordings and compliance data of the aforementioned subset of patients were prospectively collected...
September 25, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28911514/defibrillation-for-ventricular-fibrillation-a-shocking-update
#11
REVIEW
Graham Nichol, Michael R Sayre, Federico Guerra, Jeanne Poole
Cardiac arrest is defined as the termination of cardiac activity associated with loss of consciousness, of spontaneous breathing, and of circulation. Sudden cardiac arrest and sudden cardiac death (SCD) are terms often used interchangeably. Most patients with out-of-hospital cardiac arrest have shown coronary artery disease or symptoms during the hour before the event. Cardiac arrest is potentially reversible by cardiopulmonary resuscitation, defibrillation, cardioversion, cardiac pacing, or treatments targeted at the underlying disease (e...
September 19, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28706588/wearable-cardioverter-defibrillator-bridge-or-alternative-to-implantation
#12
REVIEW
Jeremie Barraud, Jennifer Cautela, Morgane Orabona, Johan Pinto, Olivier Missenard, Marc Laine, Franck Thuny, Franck Paganelli, Laurent Bonello, Michael Peyrol
The implantable cardioverter-defibrillator (ICD) is effective to prevent sudden cardiac death (SCD) in selected patients with heart disease known to be at high risk for ventricular arrhythmia. Nevertheless, this invasive and definitive therapy is not indicated in patients with potentially transient or reversible causes of sudden death, or in patients with temporary contra-indication for ICD placement. The wearable cardioverter defibrillator (WCD) is increasingly used for SCD prevention both in patients awaiting ICD implantation or with an estimated high risk of ventricular arrhythmia though to be transient...
June 26, 2017: World Journal of Cardiology
https://www.readbyqxmd.com/read/28696089/prevention-of-sudden-cardiac-death-from-wearable-to-subcutaneous-cardioverter-defibrillator
#13
Stefano Viani, Ezio Soldati, Andrea DI Cori, Luca Segreti, Luca Paperini, Raffaele DE Lucia, Giulio Zucchelli, Maria G Bongiorni
The implantable cardioverter defibrillator (ICD) is today an indisputable evidence-based treatment for cardiac sudden death both in primary and secondary prevention. However many clinical conditions that would represent an indication to ICD implantation, according to guidelines, may be potentially reversible or may be accompanied by temporary contraindications to the implant. Moreover transvenous cardioverter defibrillator implantation still carries a not negligible risk of complications both acutely and at follow-up...
July 10, 2017: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/28499628/a-real-world-wearable-cardioverter-defibrillator-experience-very-high-appropriate-shock-rate-in-ischemic-cardiomyopathy-patients-at-a-european-single-center
#14
Thomas Beiert, Robert Malotki, Natalie Kraemer, Florian Stöckigt, Markus Linhart, Georg Nickenig, Jan W Schrickel, René P Andrié
BACKGROUND: The wearable cardioverter defibrillator (WCD) has emerged as a valuable tool to protect patients with increased risk of sudden cardiac death (SCD). We sought to characterize WCD patients and to analyze predictors of ventricular arrhythmia (VA) occurrence and WCD shock delivery. METHODS AND RESULTS: One hundred fourteen patients with WCD use were included in the study. Indications were mainly ischemic cardiomyopathy (ICM; 31.6%), non-ICM (45.6%) and explantation of implantable cardioverter defibrillator due to device infection (11...
April 28, 2017: Journal of Electrocardiology
https://www.readbyqxmd.com/read/28454824/the-impact-of-body-mass-index-on-the-wearable-cardioverter-defibrillator-shock-efficacy-and-patient-wear-time
#15
Chingping Wan, Steven J Szymkiewicz, Helmut U Klein
BACKGROUND: The impact of body mass index (BMI) on the shock efficacy and patient adherence among patients using a wearable cardioverter defibrillator (WCD) is unknown. METHODS: Patients prescribed the WCD between January 1, 2008 and June 1, 2013, who experienced at least one episode of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and who received appropriate WCD therapy, were identified within a registry maintained by the manufacturer for regulatory, reimbursement, and administrative purposes...
April 2017: American Heart Journal
https://www.readbyqxmd.com/read/28429542/study-of-the-wearable-cardioverter-defibrillator-in-advanced-heart-failure-patients-swift
#16
Alon Barsheshet, Valentina Kutyifa, Theodora Vamvouris, Arthur J Moss, Yitschak Biton, Leway Chen, Eugene Storozynsky, Chingping Wan, Steven J Szymkiewicz, Ilan Goldenberg
INTRODUCTION: The wearable cardioverter defibrillator (WCD) may allow stabilization until reassessment for an implantable cardioverter defibrillator (ICD) among high-risk heart failure (HF) patients. However, there are limited data on the WCD benefit in the acute decompensated HF setting. METHODS AND RESULTS: The Study of the Wearable Cardioverter Defibrillator in Advanced Heart Failure Patients (SWIFT) was a prospective clinical trial carried out at two medical centers...
April 21, 2017: Journal of Cardiovascular Electrophysiology
https://www.readbyqxmd.com/read/28409333/the-wearable-defibrillator-a%C3%A2-most-affordable-vest
#17
EDITORIAL
J R de Groot
No abstract text is available yet for this article.
May 2017: Netherlands Heart Journal
https://www.readbyqxmd.com/read/28333373/ventricular-arrhythmias-in-patients-with-newly-diagnosed-nonischemic-cardiomyopathy-insights-from-the-prolong-study
#18
David Duncker, Thorben König, Stephan Hohmann, Johann Bauersachs, Christian Veltmann
BACKGROUND: Patients with nonischemic cardiomyopathy (NICM) reportedly have low incidence of appropriate shocks from wearable cardioverter-defibrillators (WCDs). A recent study questions the benefit from primary preventive implantation of implantable cardioverter-defibrillators in NICM. We therefore analyzed a subgroup of patients with NICM from the PROLONG study. HYPOTHESIS: Patients with newly diagnosed NICM show a risk for ventricular tachyarrhythmia. METHODS: The PROLONG study included 167 patients with newly diagnosed heart failure and left ventricular ejection fraction (LVEF) ≤35% with a WCD...
March 23, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28275862/risk-for-life-threatening-arrhythmia-in-newly-diagnosed-peripartum-cardiomyopathy-with-low-ejection-fraction-a-german-multi-centre-analysis
#19
David Duncker, Ralf Westenfeld, Torsten Konrad, Tobias Pfeffer, Carlos A Correia de Freitas, Roman Pfister, Dierk Thomas, Alexander Fürnkranz, René P Andrié, Andreas Napp, Jörn Schmitt, Laszlo Karolyi, Reza Wakili, Denise Hilfiker-Kleiner, Johann Bauersachs, Christian Veltmann
INTRODUCTION: Peripartum cardiomyopathy (PPCM) is a rare cardiomyopathy characterized by an acute reduction in left ventricular ejection fraction (LVEF). Sudden deaths during the course of PPCM are reported to be elevated, the underlying mechanisms remains unknown. The aim of the present multi-centre study was to evaluate the arrhythmia burden in a multi-centre approach in patients with PPCM using a wearable cardioverter/defibrillator (WCD). METHODS AND RESULTS: Forty-nine patients from 16 German centres with newly diagnosed PPCM and LVEF ≤35% receiving a WCD were included in this retrospective analysis...
August 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/28188473/outpatient-treatment-with-the-wearable-cardioverter-defibrillator-clinical-experience-in-two-dutch-centres
#20
A F B E Quast, V F van Dijk, A A M Wilde, R E Knops, L V A Boersma
INTRODUCTION: The latest European Society of Cardiology Guidelines recommend consideration of a wearable cardioverter-defibrillator (WCD) for patients with a poor left ventricular ejection fraction (LVEF) who are at risk of sudden arrhythmic death but are not eligible for an implantable defibrillator. For these patients a WCD can be an alternative to long-term hospitalisation. PURPOSE: To evaluate the use of WCD therapy in these patient groups in two Dutch centres...
May 2017: Netherlands Heart Journal
keyword
keyword
86356
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"